FDA panel backs Gilead's HIV prevention drug Descovy, except in women

An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.